Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 55 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Review, H2 2016', provides in depth analysis on Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted pipeline therapeutics. 

The report provides comprehensive information on the Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- The report reviews Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) Overview 7
Therapeutics Development 8
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Stage of Development 8
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Therapy Area 9
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Indication 10
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Products under Development by Companies 13
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Therapeutics Assessment 15
Assessment by Monotherapy/Combination Products 15
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Companies Involved in Therapeutics Development 22
Jyant Technologies Inc 22
NeuroNano Pharma Inc 23
Neurotez Inc 24
Novelion Therapeutics Inc 25
XL-protein GmbH 26
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Drug Profiles 27
CV-0801 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
CV-0802 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
memtin - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
metreleptin - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Monoclonal Antibody Conjugate to Agonize Leptin Receptor for Metabolic Disorders - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
Peptide to Antagonize Leptin Receptor II for Triple Negative Breast Cancer - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
Recombinant Protein to Agonize Leptin Receptor for Obesity - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
Synthetic Peptide to Agonize Leptin Receptor for Diabetes and Obesity - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
XL-100 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Dormant Projects 40
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Discontinued Products 42
Leptin Receptor (HuB219 or OB Receptor or CD295 or LEPR) - Featured News & Press Releases 43
Dec 22, 2016: Novelion Therapeutics Subsidiary Files for European Approval for Metreleptin as a treatment for Generalized Lipodystrophy and a Subset of Patients with Partial Lipodystrophy 43
Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease 44
Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin 45
Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin 45
May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy 46
Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy 47
Jul 27, 2012: Neurotez Receives US Patent 8,227,408 Covering Leptin Therapy For Alzheimer's Disease 47
Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy 48
Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy 49
Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy 50
Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy 51
Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy 52
Nov 16, 2010: Juvenile Diabetes Research Foundation And Amylin Partner To Investigate Metreleptin As Potential Therapy To Improve Blood Glucose Control In Type 1 Diabetes 53

Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 54
Disclaimer 55

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Assessment by Monotherapy/Combination Products, H2 2016 15
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Pipeline by Jyant Technologies Inc, H2 2016 22
Pipeline by NeuroNano Pharma Inc, H2 2016 23
Pipeline by Neurotez Inc, H2 2016 24
Pipeline by Novelion Therapeutics Inc, H2 2016 25
Pipeline by XL-protein GmbH, H2 2016 26
Dormant Projects, H2 2016 40
Dormant Projects (Contd..1), H2 2016 41
Discontinued Products, H2 2016 42